Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
announced today that Daniel Teper, Chief Executive Officer of Immune
Pharmaceuticals presented at the 6th Annual OneMedForum, on
Wednesday, January 9, 2013 at 1:40 PM Pacific time at The Sir Francis
Drake hotel in San Francisco, California. Mr. Teper presented a company
overview.
The webcast of Mr. Teper’s presentation will be accessible within a few
days and for the next 90 days at www.epicept.com.
Merger Details
In November 2012, Immune Pharmaceuticals Ltd. (“Immune”), a privately
held Israeli company, and EpiCept Corporation (“EpiCept”) (NASDAQ OMX
Stockholm Exchange and OTCQX: EPCT) announced that they entered into a
definitive merger agreement. The transaction is anticipated to close
during the first quarter of 2013 and is subject to satisfaction of
certain customary closing conditions, including the approval of a
majority of EpiCept shareholders.
About EpiCept Corporation
EpiCept is focused on the development and commercialization of
pharmaceutical products for the treatment of pain and cancer. The
Company's pain portfolio includes AmiKet™, a prescription topical
analgesic cream in late-stage clinical development designed to provide
effective long-term relief of pain associated with peripheral
neuropathies. The Company's product Ceplene®, when used
concomitantly with low-dose IL-2 is intended as remission maintenance
therapy in the treatment of AML for adult patients who are in their
first complete remission. The Company sold all of its rights to Ceplene®
in Europe and certain Pacific Rim countries and a portion of its
remaining Ceplene® inventory to Meda AB in June 2012. Ceplene®
is licensed to MegaPharm Ltd. to market and sell in Israel and EpiCept
has retained its rights to Ceplene® in all other countries,
including countries in North and South America. The Company has other
oncology drug candidates in clinical development that were discovered
using in-house technology and have been shown to act as vascular
disruption agents in a variety of solid tumors.
Forward-Looking Statements
This news release and any oral statements made with respect to the
information contained in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. You are urged to consider statements that include
the words “may,” “will,” “would,” “could,” “should,” “believes,”
“estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,”
“intends,” “continues,” “forecast,” “designed,” “goal,” or the negative
of those words or other comparable words to be uncertain and
forward-looking. Such forward-looking statements include statements
which express plans, anticipation, intent, contingency, goals, targets,
future development and are otherwise not statements of historical fact.
These statements are based on our current expectations and are subject
to risks and uncertainties that could cause actual results or
developments to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Factors that may cause actual results or developments to
differ materially include: the risk that we may be unable to complete
the proposed merger transaction with Immune Pharmaceuticals, the risks
associated with the adequacy of our existing cash resources and our
ability to continue as a going concern, the risks associated with our
ability to continue to meet our obligations under our existing debt
agreements, the risk that Azixa® will not receive regulatory
approval or achieve significant commercial success, the risk that
clinical trials for AmiKet™ or crolibulinTM will not be
successful, the risk that AmiKet™ or crolibulinTM will not
receive regulatory approval or achieve significant commercial success,
the risk that we will not be able to find a partner to help conduct the
Phase III trials for AmiKet™ on attractive terms, a timely basis or at
all, the risk that Ceplene® will not receive regulatory
approval or marketing authorization in the United States or Canada, the
risk that Ceplene® will not achieve significant commercial
success, the risk that our other product candidates that appeared
promising in early research and clinical trials do not demonstrate
safety and/or efficacy in larger-scale or later-stage clinical trials,
the risk that we will not obtain approval to market any of our product
candidates, the risks associated with dependence upon key personnel, the
risks associated with reliance on collaborative partners and others for
further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our
history of operating losses since our inception; the highly competitive
nature of our business; risks associated with litigation; and risks
associated with our ability to protect our intellectual property. These
factors and other material risks are more fully discussed in our
periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and
other filings with the U.S. Securities and Exchange Commission. You are
urged to carefully review and consider the disclosures found in our
filings which are available at www.sec.gov
or at www.epicept.com.
You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be wrong due to inaccurate
assumptions, unknown risks or uncertainties or other risk factors.
EPCT-GEN
